Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 51Breast Neoplasms 40Colorectal Neoplasms 26Prostatic Neoplasms 22Lung Neoplasms 18Carcinoma, Non-Small-Cell Lung 15Carcinoma, Hepatocellular 15Stomach Neoplasms 14Hematologic Neoplasms 10Brain Neoplasms 10Pancreatic Neoplasms 9Colonic Neoplasms 9Urinary Bladder Neoplasms 8Lymphoma, Follicular 8Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Ovarian Neoplasms 7Melanoma 7Liver Neoplasms 7Leukemia, Myeloid, Acute 7Disease 7Anxiety Disorders 7Myasthenia Gravis 6Multiple Myeloma 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Rectal Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × TNBC × 1 year × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡